Scaling for growth
2023 Annual Report
Our purpose is to invest to extend and enhance human life
Watch video
Our team members are experts at what they do
Our people
A diversified portfolio of life science companies
Portfolio

To unlock the potential from truly innovative science to transform patients’ lives

We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses

Who we are

A diversified portfolio across clinical stages

Late-stage clinical companies
Late-stage clinical companies
Clinical companies
Clinical companies
Pre-clinical companies
Pre-clinical companies
Explore our portfolio

Making a positive contribution

We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.

Sustainability

Latest videos

Expansion of our senior team

| Video length 7:06

Launching Beacon Therapeutics

| Video length 7:36

Scaling for growth

| Video length 09:28

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

| Video length 7:43

Syncona CEO Martin Murphy discusses Clade Series A financing

| Video length 10:16

Anaveon doses first patient

| Video length 6:18

Introduction to Richard Francis, Chief Executive of Purespring Therapeutics

| Video length 3:42

Introduction from Quell Therapeutics, CEO, Iain McGill

| Video length 5:38

Quell: the science and the unmet medical need for patients

| Video length 5:25

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

| Video length 4:25

Introducing Resolution Therapeutics

| Video length 11:28

Introduction to Purespring

| Video length 5:47

Syncona FY20: Martin Murphy discusses FY20 results

| Video length 6:15

Syncona FY20: Martin Murphy discusses the impact of COVID-19

| Video length 4:52

Syncona FY20: Martin Murphy discusses the outlook for Syncona

| Video length 2:53

Achilles doses first patient

| Video length 1:40

Gene Therapy explained

| Video length 3:11

Building Syncona’s Gene Therapy platform

| Video length 7:02
View all videos

Latest insights

Challenges continue but brighter days on the horizon

Navigating the biotech landscape: A journey from big pharma to innovative startups

Building a platform for the next generation of investors

Expansion of our senior team

Modality precision is the new precision in medicine

Taking a proactive approach to portfolio company sustainability

Launching Beacon Therapeutics

Leveraging the Syncona team for our next phase of growth

Good science must survive in challenging markets

Scaling for growth

Building a global leader in retinal gene therapy

Welcoming our first Windsor Fellowship intern to Syncona

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

Syncona CEO Martin Murphy discusses Clade Series A financing

Alex Hamilton on manufacturing in cell and gene therapy and the role of development partnerships

Ed Hodgkin provides his perspectives from a career in early-stage biotech

Encouraging diversity in the next generation of scientists

Anaveon doses first patient

View all insights and articles

Latest news

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Century Therapeutics to acquire Clade Therapeutics

Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Autolus Therapeutics announces publication in Blood Cancer Journal

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Therapeutics announces publication in Nature Communications

Freeline Shareholders Approve Acquisition by Syncona

FY2023/4 Third Quarter Update

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

View all news
2023 Annual Report front cover

2023 Annual Report

Our Annual Report and Accounts 2023 provides an overview of our most recent financial year, as we continue to deliver on behalf of our stakeholders.

28.06.23 | pdf (4.25Mb)
Download

An expert multi-disciplinary team, attracting world-class talent

We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.

Our people

Investment team key facts

All as of 31 December 2023

12

Members of the investment team

171

Years of life science and investment expertise

83%

Investment team with PhDs

Search